MLYS
Mineralys Therapeutics, Inc.Company Information
- Company Name
- Mineralys Therapeutics, Inc.
- CIK
- CIK0001933414
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- MLYS: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MLYS
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-30
- Last sale
- 2026-09-22
- Shares purchased (TTM)
- 58,300
- Shares sold (TTM)
- 2,116,255
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 96,966,534
- Shares outstanding
- 84,727,282
- Ownership
- 114.45%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- 3.22%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Series A Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 138 | 113 | 173 | 218 | 102 | 165 | 114 | 97 | 68 | 90 | 49 | 86 | ||||||
| Debt Securities Current | 523 | 533 | 484 | 376 | 223 | 178 | 84 | 166 | 243 | 248 | 187 | 167 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 6 | 5 | 6 | 10 | 11 | 7 | 4 | 7 | 8 | 13 | 12 | ||||||
| Assets Current | 666 | 652 | 661 | 600 | 335 | 355 | 205 | 268 | 318 | 347 | 249 | 265 | ||||||
| Debt Securities Held To Maturity Amortized Cost After Allowance For Credit Loss Noncurrent | - | - | - | - | - | - | - | 0 | 0 | 0 | 2 | 12 | ||||||
| Marketable Securities Noncurrent | - | - | - | - | - | - | 0 | - | - | - | 2 | - | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Other Assets Noncurrent | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 668 | 653 | 662 | 600 | 336 | 355 | 206 | 268 | 318 | 347 | 252 | 278 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 2 | 1 | 3 | 0 | 0 | 3 | 2 | 4 | 1 | 6 | ||||||
| Accrued Liabilities Current | 18 | 14 | 13 | 22 | 19 | 13 | 14 | 28 | 27 | 15 | 10 | 8 | ||||||
| Liabilities Current | 19 | 15 | 15 | 24 | 22 | 13 | 15 | 31 | 28 | 19 | 10 | 14 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Secured Long Term Debt | 98 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities | 117 | - | - | - | - | - | - | - | - | - | - | - | ||||||
Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,288 | 1,135 | 1,104 | 1,001 | 702 | 686 | 494 | 490 | 487 | 484 | 366 | 364 | ||||||
| Retained Earnings Accumulated Deficit | -738 | -497 | -457 | -425 | -388 | -345 | -303 | -254 | -197 | -156 | -125 | -100 | ||||||
| Stockholders Equity | 551 | 638 | 647 | 576 | 314 | 342 | 191 | 237 | 290 | 328 | 241 | 264 | ||||||
| Liabilities And Stockholders Equity | 668 | 653 | 662 | 600 | 336 | 355 | 206 | 268 | 318 | 347 | 252 | 278 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 88 | 82 | 82 | 79 | 66 | 65 | 50 | 50 | 50 | 50 | 41 | 41 | ||||||
| Shares Outstanding | 88 | 82 | 82 | 79 | 66 | 65 | 50 | 50 | 50 | 50 | 41 | 41 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMineralys Therapeutics, Inc. (MLYS) — SEC Financial Statements & Analysis
Mineralys Therapeutics, Inc. (MLYS) is a pharmaceutical preparations company. Mineralys Therapeutics, Inc. trades on Nasdaq as: MLYS. Mineralys Therapeutics, Inc. (MLYS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Mineralys Therapeutics, Inc. carries a market cap of $2.29B, a P/E ratio of -6.54x, a P/B ratio of 4.15x, an enterprise value of $2.25B, and an EV/EBITDA multiple of -6.06x. On profitability, it posts a Return on Equity (ROE) of -80.88%, a Return on Assets (ROA) of -69.67%, and a Return on Invested Capital (ROIC) of -102.71%. Per share, it reports EPS of $-4.13, diluted EPS of $-4.13, free cash flow per share of $-1.64, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 83.24% year-over-year and EPS growth of 41.55% year-over-year. On the balance sheet, it maintains a current ratio of 34.46x, a quick ratio of 34.24x, working capital of $646.48M, a debt-to-equity ratio of 0.21x, a debt ratio of 0.18, an interest coverage ratio of -17.50x, free cash flow of $-138.80M (TTM), and net debt of $-40.65M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.29B
- P/E TTM
- -6.54x
- EPS TTM
- $-4.13
- P/B TTM
- 4.15x
- ROE TTM
- -80.88%
- ROA TTM
- -69.67%
- Debt To Equity
- 0.21x
- Free Cash Flow TTM
- $-138.80M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Mineralys Therapeutics, Inc. in?
Mineralys Therapeutics, Inc. (MLYS) operates in the Pharmaceutical Preparations industry.
What exchange does MLYS trade on?
Mineralys Therapeutics, Inc. (MLYS) trades on the Nasdaq.
When was Mineralys Therapeutics, Inc. (MLYS)'s most recent SEC filing?
Mineralys Therapeutics, Inc. (MLYS)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is MLYS's market cap?
Mineralys Therapeutics, Inc. (MLYS) has a market capitalization of $2.29B as of 2026-06-30.
What is MLYS's EPS (earnings per share)?
Mineralys Therapeutics, Inc. (MLYS)'s trailing twelve month EPS is $-4.13 as of 2026-06-30.
What is MLYS's ROE (return on equity)?
Mineralys Therapeutics, Inc. (MLYS)'s trailing twelve month Return on Equity (ROE) is -80.88% as of 2026-06-30.
What is MLYS's ROA (return on assets)?
Mineralys Therapeutics, Inc. (MLYS)'s trailing twelve month Return on Assets (ROA) is -69.67% as of 2026-06-30.
What is MLYS's ROIC (return on invested capital)?
Mineralys Therapeutics, Inc. (MLYS)'s trailing twelve month Return on Invested Capital (ROIC) is -102.71% as of 2026-06-30.
What is MLYS's EV/EBITDA?
Mineralys Therapeutics, Inc. (MLYS)'s trailing twelve month EV/EBITDA is -6.06x as of 2026-06-30.